CVS Caremark After Earnings: Solid Returns Ahead

CVS Caremark is delivering solid financial performance, and the company looks attractively valued in comparison to peers such as Walgreen and Rite Aid, leaving it well positioned for healthy returns.

May 2, 2014 at 2:43PM


Source: CVS Caremark.

CVS Caremark (NYSE:CVS) reported sound financial performance for the first quarter of 2014, even if earnings came in below analysts' expectations. The company is outperforming competitors such as Walgreen (NASDAQ:WBA) and Rite Aid (NYSE:RAD), both over the last several years and in recent months. However, when comparing valuation ratios for CVS Caremark versus Walgreen and Rite Aid, the stock looks attractively valued. CVS Caremark looks well positioned for solid returns in the years ahead.

Healthy performance
Sales during the first quarter of 2014 increased by 6.3% to $32.69 billion, marginally above Wall Street estimates of $32.54 billion for the quarter. Earnings per share came in below expectations, though, as the company made $1.02 in adjusted earnings per share versus an average forecast of $1.04 per share for the period.

It's worth noting that this still represents a big increase of 22.5% in adjusted earnings per share versus the same quarter in the prior year, quite an impressive performance for a big company in a mature industry such as CVS Caremark. 

Besides, CVS was affected by harsh weather conditions and a weak flu season during the quarter, and this had a transitory negative impact on performance.

Revenues in the retail pharmacy segment increased by a lackluster 2.7% during the quarter, with same-store sales growing 1.4%. While pharmacy same-store sales increased by 3.8% during the period, front-end same-store sales were 3.8% lower, and this was the weakest spot in the report.

On the other hand, the pharmacy services segment was remarkably strong, with sales growing by 10% to $20.2 billion during the quarter. This segment is not only important in terms of financial contribution for CVS Caremark, but it also has big strategic advantages for the company in areas such as vertical integration, economies of scale, and overall competitive strength.

CVS Caremark reiterated its guidance for 2014, with total sales expected to increase by between 5.25% and 6.5% and adjusted earnings per share forecast to grow by 10.25% to 13.75% during the year. In spite of a weaker-than-expected first quarter, management seems confident of the company's ability to deliver solid performance in the rest of the year.

Growth and valuation
CVS has materially outgrown competitors such as Walgreen and Rite Aid over the last several years, and the company continues to outperform according to recent financial reports.

CVS Revenue (TTM) Chart

CVS Revenue (TTM) data. Source: YCharts.

Walgreen announced a sales increase of 4.5% in March to $6.43 billion, and total comparable-store sales grew by 3.5% during the month, but Walgreen was also affected by an unusually cold winter that hurt front-end sales. Total front-end sales fell by 2.6%, while comparable-store front-end sales decreased by 3.4% during the month.

Rite Aid has been implementing a remarkable turnaround over the last several quarters, and the company is clearly moving in the right direction when it comes to streamlining operations in order to improve profitability. However, Rite Aid is no match to CVS Caremark when it comes to sales growth.

Rite Aid announced an increase of 0.7% in same-store sales for the month of March, as front-end same-store sales fell by 0.5% and pharmacy same-store sales increased 3.5% during the period.

However, Rite Aid has already announced sales for April, and performance was much more encouraging. Rite Aid delivered an increase of 5% in same-store sales during April; pharmacy same-store sales increased by 5.2% during the month, while front-end same-store sales showed a healthy rebound with an increase of 4.7%.

Improving front-end sales from Rite Aid bode well for CVS Caremark and Walgreen over the following months, as it could be indicating that the industry is moving beyond the negative headwinds produced by the unusually harsh winter.

In spite of its superior financial performance, CVS Caremark trades at a valuation discount versus both Walgreen and Rite Aid when comparing P/E ratios. CVS Caremark has a P/E ratio below 20, while Walgreen trades at a P/E multiple above 24 and Rite Aid at an even higher P/E ratio of almost 35.

Superior performance merits a higher valuation, so CVS Caremark is offering considerable upside potential from current levels.

Foolish takeaway
CVS Caremark delivered lower-than-expected earnings for the last quarter, but the company is still performing soundly, and management is confident in its ability to deliver according to guidance for the rest of the year. When compared against Walgreen and Rite Aid, CVS looks like an attractive option in terms of growth versus valuation, so the company looks well positioned to deliver healthy returns for investors.

You don't want to miss our best pick for 2014!
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Andrés Cardenal has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information